Simulation optimization of PSA-threshold based prostate cancer screening policies

被引:17
|
作者
Underwood, Daniel J. [1 ]
Zhang, Jingyu [2 ]
Denton, Brian T. [1 ]
Shah, Nilay D. [3 ]
Inman, Brant A. [4 ]
机构
[1] N Carolina State Univ, Edward P Fitts Dept Ind & Syst Engn, Raleigh, NC 27695 USA
[2] Philips Res N Amer, Briarcliff Manor, NY 10510 USA
[3] Mayo Clin, Div Hlth Care Policy & Res, Rochester, MN 55905 USA
[4] Duke Univ, Med Ctr, Div Urol, Durham, NC 27710 USA
基金
美国国家科学基金会;
关键词
Prostate cancer screening; Simulation optimization; Genetic algorithm; Ranking and selection; SATURATION BIOPSY; UNITED-STATES; SELECTION; PROBABILITY; MORTALITY; AUTOPSY; SUBSET; SYSTEM; IMPACT; RISK;
D O I
10.1007/s10729-012-9195-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
We describe a simulation optimization method to design PSA screening policies based on expected quality adjusted life years (QALYs). Our method integrates a simulation model in a genetic algorithm which uses a probabilistic method for selection of the best policy. We present computational results about the efficiency of our algorithm. The best policy generated by our algorithm is compared to previously recommended screening policies. Using the policies determined by our model, we present evidence that patients should be screened more aggressively but for a shorter length of time than previously published guidelines recommend.
引用
收藏
页码:293 / 309
页数:17
相关论文
共 50 条
  • [31] PSA testing for prostate cancer screening Reply
    Cuzick, Jack
    Thorat, Mangesh A.
    LANCET ONCOLOGY, 2015, 16 (01): : E3 - E3
  • [32] New studies on PSA screening for prostate cancer
    Martin
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (11) : 605 - 605
  • [33] PSA screening and prostate cancer risk reduction
    Andriole, Gerry L., Jr.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (06) : 936 - 937
  • [34] New recommendations for prostate cancer screening with PSA
    Julia-Romero, C.
    Rechi-Sierra, K.
    Juan-Escudero, J. U.
    MEDICINA DE FAMILIA-SEMERGEN, 2021, 47 (05): : 342 - 347
  • [35] PSA screening for prostate cancer:: The current controversy
    de Koning, HJ
    Schröder, FH
    ANNALS OF ONCOLOGY, 1998, 9 (12) : 1293 - 1296
  • [36] Optimization of PSA Screening Policies: A Comparison of the Patient and Societal Perspectives
    Zhang, Jingyu
    Denton, Brian T.
    Balasubramanian, Hari
    Shah, Nilay D.
    Inman, Brant A.
    MEDICAL DECISION MAKING, 2012, 32 (02) : 337 - 349
  • [37] Prostate cancer and prostate specific antigen (PSA) screening in Austria
    Vutuc, C
    Schernhammer, ES
    Haidinger, G
    Waldhör, T
    WIENER KLINISCHE WOCHENSCHRIFT, 2005, 117 (13-14) : 457 - 461
  • [38] Prostate cancer and prostate-specific antigen (PSA) screening in AustriaProstatakarzinom und PSA-Screening in Österreich
    Christian Vutuc
    Eva S. Schernhammer
    Gerald Haidinger
    Thomas Waldhör
    Wiener klinische Wochenschrift, 2005, 117 : 457 - 461
  • [39] Re: Reconsidering Prostate Cancer Mortality- The Future of PSA Screening Against increasing PSA threshold to 10 ng/ml
    Zlotta, Alexandre R.
    Carlsson, Sigrid V.
    Finelli, Antonio
    Fleshner, Neil E.
    EUROPEAN UROLOGY, 2020, 78 (06) : 927 - 929
  • [40] PSA-based screening for prostate cancer: How does it compare with other cancer screening tests?
    Crawford, E. David
    Abrahamsson, Per-Anders
    EUROPEAN UROLOGY, 2008, 54 (02) : 262 - 273